这篇文章不错，转发给_老虎社区_美港股上老虎

_______8845
2020-06-05

这篇文章不错，转发给大家看看

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk A/S NVO reported first-quarter 2020 earnings of 75 cents per American Depositary Receip

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":958516730,"tweetId":"958516730","gmtCreate":1591312912120,"gmtModify":1704195291312,"author":{"id":3526353410730916,"authorId":3526353410730916,"authorIdStr":"3526353410730916","name":"_______8845","avatar":"https://static.tigerbbs.com/aecf164c9ef6fa468b57f6a24a381c4d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","htmlText":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/958516730","repostId":2034801632,"repostType":2,"repost":{"id":"2034801632","pubTimestamp":1588864683,"share":"https://www.laohu8.com/m/news/2034801632?lang=&edition=full","pubTime":"2020-05-07 23:18","market":"us","language":"en","title":"Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2034801632","media":"Zacks","summary":"Novo Nordisk A/S NVO reported first-quarter 2020 earnings of 75 cents per American Depositary Receip","content":"<html><body><div>Novo Nordisk A/S NVO reported first-quarter 2020 earnings of 75 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of 73 cents and increasing 16% in DKK from the year-ago quarter.Revenues grew 16% year over year in DKK (up 14% at constant exchange rate [CER]) to $5.0 billion. Revenues beat the Zacks Consensus Estimate of $4.70 billion. COVID-19-related stockpiling led to the upside.Novo Nordisk AS Price, Consensus and EPS SurpriseNovo Nordisk AS price-consensus-eps-surprise-chart | Novo Nordisk AS QuoteNovo Nordisk’s shares have gained 7.1% in the year so far against the industry’s decline of 1.8%.All growth rates mentioned below are on a year-over-year basis.Quarter in DetailNovo Nordisk operates in two segments — Diabetes and Obesity Care, and Biopharmaceuticals.The Diabetes and Obesity Care segment sales grew 14% at CER. In Diabetes Care, fast-acting insulin (Fiasp and NovoRapid) revenues grew 1% and Human insulin revenues were up 11%. Premix insulin (Ryzodeg and NovoMix) revenues rose 7%. However, sales of long-acting insulin (Tresiba, Xultophy and Levemir) declined 3%. Ozempic had a strong launch and recorded sales of DKK 4.7 billion in the quarter.Obesity Care (Saxenda) grew 30% at CER. Sales at the Biopharmaceuticals segment increased 16% at CER to DKK 5.3 billion. Hemophilia sales (NovoSeven and NovoEight) were up 9% to DKK 2.8 billion.Research and development (R&amp;D) expenses increased 40% at CER due to the reversal of write-downs of prelaunch inventory in the year-ago quarter following the filing of oral semaglutide to the FDA.Sales and distribution costs rose 7% at CER driven by promotional activities for Ozempic.Other UpdatesIn April 2020, the European Commission (EC) granted marketing authorization to Rybelsus for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise.Novo Nordisk submitted a new drug application to the China Center of Drug Evaluation for Ozempic in February both for treating insufficiently controlled type 2 diabetes and reducing the risk of major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.In April, the company completed a phase II trial with subcutaneous semaglutide in non-alcoholic steatohepatitis (NASH).2020 Outlook MaintainedNovo Nordisk maintained its outlook for 2020 amid the coronavirus pandemic. It expects 3-6% sales growth at CER. This reflects a strong performance for the glucagon-like peptide-1 (GLP-1)-based diabetes care products, Ozempic, Victoza and Rybelsus; the obesity care product, Saxenda; the portfolio of new-generation insulin; and the contribution from biopharm products, Esperoct, Refixia and NovoEight.However, this is expected to be partly offset by intensifying global competition within the Diabetes Care and Biopharmaceuticals segments, especially for hemophilia inhibitor. We note that Novo Nordisk faces stiff competition from Eli Lilly LLY and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> SNY in the global insulin market. The company also faces stiff competition from Eli Lilly and Astra Zeneca AZN in the global GLP-1 market.<div>Persistent pricing pressure within Diabetes Care, especially in the United States, might also negatively impact sales.Our TakeNovo Nordisk beats on both first-quarter earnings and sales. Ryzodeg continues to gain traction and Ozempic is off to a solid start. However, the impact of COVID-19 will affect the performance in the upcoming quarters.Novo Nordisk currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.5 Stocks Set to DoubleEach was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs &gt;&gt; Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report   Novo Nordisk AS (NVO) : Free Stock Analysis Report   Sanofi (SNY) : Free Stock Analysis Report   AstraZeneca <a href=\"https://laohu8.com/S/PLC\">PLC</a> (AZN) : Free Stock Analysis Report   Eli Lilly and Company (LLY) : Free Stock Analysis Report   To read this article on Zacks.com click here.   Zacks Investment Research</div></div></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-05-07 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novo-nordisks-nvo-q1-earnings-151803675.html>Zacks</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nNovo Nordisk A/S NVO reported first-quarter 2020 earnings of 75 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of 73 cents and increasing 16% in DKK from the year-...\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisks-nvo-q1-earnings-151803675.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/lo/api/res/1.2/2F.SoboO5_cCNF74gWo.6g--/YXBwaWQ9eXZpZGVvZmVlZHM7dz02MzU7aD00MDA-/https://media.zenfs.com/en-us/zacks.com/9883d206905e7516b2353476e213e60c","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://finance.yahoo.com/news/novo-nordisks-nvo-q1-earnings-151803675.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2034801632","content_text":"Novo Nordisk A/S NVO reported first-quarter 2020 earnings of 75 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of 73 cents and increasing 16% in DKK from the year-ago quarter.Revenues grew 16% year over year in DKK (up 14% at constant exchange rate [CER]) to $5.0 billion. Revenues beat the Zacks Consensus Estimate of $4.70 billion. COVID-19-related stockpiling led to the upside.Novo Nordisk AS Price, Consensus and EPS SurpriseNovo Nordisk AS price-consensus-eps-surprise-chart | Novo Nordisk AS QuoteNovo Nordisk’s shares have gained 7.1% in the year so far against the industry’s decline of 1.8%.All growth rates mentioned below are on a year-over-year basis.Quarter in DetailNovo Nordisk operates in two segments — Diabetes and Obesity Care, and Biopharmaceuticals.The Diabetes and Obesity Care segment sales grew 14% at CER. In Diabetes Care, fast-acting insulin (Fiasp and NovoRapid) revenues grew 1% and Human insulin revenues were up 11%. Premix insulin (Ryzodeg and NovoMix) revenues rose 7%. However, sales of long-acting insulin (Tresiba, Xultophy and Levemir) declined 3%. Ozempic had a strong launch and recorded sales of DKK 4.7 billion in the quarter.Obesity Care (Saxenda) grew 30% at CER. Sales at the Biopharmaceuticals segment increased 16% at CER to DKK 5.3 billion. Hemophilia sales (NovoSeven and NovoEight) were up 9% to DKK 2.8 billion.Research and development (R&D) expenses increased 40% at CER due to the reversal of write-downs of prelaunch inventory in the year-ago quarter following the filing of oral semaglutide to the FDA.Sales and distribution costs rose 7% at CER driven by promotional activities for Ozempic.Other UpdatesIn April 2020, the European Commission (EC) granted marketing authorization to Rybelsus for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise.Novo Nordisk submitted a new drug application to the China Center of Drug Evaluation for Ozempic in February both for treating insufficiently controlled type 2 diabetes and reducing the risk of major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.In April, the company completed a phase II trial with subcutaneous semaglutide in non-alcoholic steatohepatitis (NASH).2020 Outlook MaintainedNovo Nordisk maintained its outlook for 2020 amid the coronavirus pandemic. It expects 3-6% sales growth at CER. This reflects a strong performance for the glucagon-like peptide-1 (GLP-1)-based diabetes care products, Ozempic, Victoza and Rybelsus; the obesity care product, Saxenda; the portfolio of new-generation insulin; and the contribution from biopharm products, Esperoct, Refixia and NovoEight.However, this is expected to be partly offset by intensifying global competition within the Diabetes Care and Biopharmaceuticals segments, especially for hemophilia inhibitor. We note that Novo Nordisk faces stiff competition from Eli Lilly LLY and Sanofi SNY in the global insulin market. The company also faces stiff competition from Eli Lilly and Astra Zeneca AZN in the global GLP-1 market.Persistent pricing pressure within Diabetes Care, especially in the United States, might also negatively impact sales.Our TakeNovo Nordisk beats on both first-quarter earnings and sales. Ryzodeg continues to gain traction and Ozempic is off to a solid start. However, the impact of COVID-19 will affect the performance in the upcoming quarters.Novo Nordisk currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.5 Stocks Set to DoubleEach was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk AS (NVO) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":821,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}